http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114832014-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate | 2022-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114832014-B |
| titleOfInvention | Application of NK cells, NK cell reinfusion preparations and combination preparations |
| abstract | The invention provides application of NK cells, NK cell reinfusion preparation and combined preparation. NK cell reinfusion can prevent cytomegalovirus infection, clear cytomegalovirus infection, and promote the immune reconstruction of NK cells. NK cell reinfusion is safe and resistant to Good receptivity, no serious side effects related to infusion, and the use of NK cell reinfusion will not lead to the emergence of virus-resistant strains, nor will it cause a series of drug side effects such as obvious bone marrow suppression and renal function damage. Moreover, the NK cells reconstituted in patients after NK cell reinfusion were more mature in phenotype and stronger in function. |
| priorityDate | 2022-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 103.